Maze Therapeutics, Inc. (MAZE)
Nasdaq: MAZE · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2024
Who owns Maze Therapeutics, Inc.
As filed with the SECHolders of 5% or more
6
ARCH Venture Fund X, L.P. holds 9.4% of Common Stock par value $0.0001 per share, as its SCHEDULE 13G filed May 15, 2025 says.
Directors and officers
18
report now, of 21 people on the record since 2025. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
ARCH Venture Fund X, L.P.
SCHEDULE 13G · filed May 15, 2025 · Common Stock par value $0.0001 per share
Third Rock Ventures IV, L.P.
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, $0.001 par value per share · 13.9% in May 9, 2025
Deep Track Capital, LP
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, $0.001 par value per share · 6.91% in Feb 7, 2025
Frazier Life Sciences Public Fund, L.P.
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock - par value $0.001 per share · 7.7% in Aug 14, 2025
Janus Henderson Group PLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock · 7.3% in Nov 14, 2025
Blackrock, Inc.
SCHEDULE 13G · filed Jul 29, 2026 · Common Stock
Matrix Capital Management Company, LP
SCHEDULE 13G/A · filed Nov 13, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5.7% in May 14, 2025
Alphabet Holdings LLC
SCHEDULE 13G/A · filed Feb 6, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5.5% in May 9, 2025
James Tananbaum
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.001 · reported falling below 5%, from 5.6% in Feb 7, 2025
Paradigm BioCapital Advisors LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.001 par value per share · reported falling below 5%, from 6.1% in Apr 1, 2026
What MAZE reports owning in othersstakes of 5% or more, and other ties
Maze Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
100sales
0purchases
82sales on a scheduled plan
6people selling
$25.0Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 4, 2025 to Nov 4, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 4, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 36 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Bernstein Harold | President, R&D & CMO | 30 | $9.5M | 26 | 0 | $0 |
| Coloma Jason V | Chief Executive Officer | 29 | $7.2M | 25 | 0 | $0 |
| Dandekar Atul | CSBO | 22 | $5.5M | 18 | 0 | $0 |
| Bachrodt Amy | SVP, Finance | 13 | $1.6M | 13 | 0 | $0 |
| Sohn Catherine A. | director | 2 | $1.1M | 0 | 0 | $0 |
| Courtney Phillips | GC and Corp. Secretary | 4 | $100,000 | 0 | 0 | $0 |